.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG06_Alemtuzumab.Alemtuzumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG06_Alemtuzumab.Alemtuzumab| name: | Alemtuzumab |
| ATC code: | L04AG06 | route: | intravenous |
| n-compartments | 2 |
Alemtuzumab is a humanized monoclonal antibody directed against CD52, a protein present on the surface of mature lymphocytes, and is primarily used as an immunosuppressive agent in multiple sclerosis and previously in B-cell chronic lymphocytic leukemia (CLL). Its main purpose is to reduce relapse rates in relapsing forms of multiple sclerosis. It is an approved drug for use in several countries.
Population pharmacokinetics in patients with relapsing multiple sclerosis receiving intravenous alemtuzumab infusions.
Admiraal, R, et al., & Bredius, RGM (2019). Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome. Clinical pharmacokinetics 58(12) 1609–1620. DOI:10.1007/s40262-019-00782-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31131436
Achini-Gutzwiller, FR, et al., & Moes, DJAR (2023). Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study. Blood advances 7(16) 4462–4474. DOI:10.1182/bloodadvances.2022009051 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37285798
Ishizawa, K, et al., & Tobinai, K (2017). Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Japanese journal of clinical oncology 47(1) 54–60. DOI:10.1093/jjco/hyw146 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28122892